Literature DB >> 29708042

The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Alan K Davis1, Joseph P Barsuglia2, Rafael Lancelotta3, Robert M Grant4, Elise Renn2.   

Abstract

BACKGROUND/AIM: 5-Methoxy- N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in several plants and in high concentrations in Bufo alvarius toad venom. Synthetic, toad, and plant-sourced 5-MeO-DMT are used for spiritual and recreational purposes and may have psychotherapeutic effects. However, the use of 5-MeO-DMT is not well understood. Therefore, we examined patterns of use, motivations for consumption, subjective effects, and potential benefits and consequences associated with 5-MeO-DMT use.
METHODS: Using internet-based advertisements, 515 respondents ( Mage=35.4. SD=11.7; male=79%; White/Caucasian=86%; United States resident=42%) completed a web-based survey.
RESULTS: Most respondents consumed 5-MeO-DMT infrequently (<once/year), for spiritual exploration, and had used less than four times in their lifetime. The majority (average of 90%) reported moderate-to-strong mystical-type experiences ( Mintensity=3.64, SD=1.11; range 0-5; e.g., ineffability, timelessness, awe/amazement, experience of pure being/awareness), and relatively fewer (average of 37%) experienced very slight challenging experiences ( Mintensity=0.95, SD=0.91; range 0-5; e.g., anxiousness, fear). Less than half (39%) reported repeated consumption during the same session, and very few reported drug craving/desire (8%), or legal (1%), medical (1%), or psychiatric (1%) problems related to use. Furthermore, of those who reported being diagnosed with psychiatric disorders, the majority reported improvements in symptoms following 5-MeO-DMT use, including improvements related to post-traumatic stress disorder (79%), depression (77%), anxiety (69%), and alcoholism (66%) or drug use disorder (60%).
CONCLUSION: Findings suggest that 5-MeO-DMT is used infrequently, predominantly for spiritual exploration, has low potential for addiction, and might have psychotherapeutic effects. Future research should examine the safety and pharmacokinetics of 5-MeO-DMT administration in humans using rigorous experimental designs.

Entities:  

Keywords:  5-MeO-DMT; 5-methoxy-N,N-dimethyltryptamine; Epidemiology; tryptamines

Mesh:

Substances:

Year:  2018        PMID: 29708042      PMCID: PMC6248886          DOI: 10.1177/0269881118769063

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  36 in total

Review 1.  The pharmacology of psilocybin.

Authors:  Torsten Passie; Juergen Seifert; Udo Schneider; Hinderk M Emrich
Journal:  Addict Biol       Date:  2002-10       Impact factor: 4.280

Review 2.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

3.  Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.

Authors:  Joseph J Palamar; Silvia S Martins; Mark K Su; Danielle C Ompad
Journal:  Drug Alcohol Depend       Date:  2015-09-03       Impact factor: 4.492

4.  Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis.

Authors:  B Sadzot; J M Baraban; R A Glennon; R A Lyon; S Leonhardt; C R Jan; M Titeler
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  Potential Therapeutic Effects of Psilocybin.

Authors:  Matthew W Johnson; Roland R Griffiths
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

Review 6.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

Review 7.  The pharmacology of lysergic acid diethylamide: a review.

Authors:  Torsten Passie; John H Halpern; Dirk O Stichtenoth; Hinderk M Emrich; Annelie Hintzen
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

8.  Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine.

Authors:  D G Spencer; T Glaser; J Traber
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  Psychedelics and mental health: a population study.

Authors:  Teri S Krebs; Pål-Ørjan Johansen
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

10.  Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells.

Authors:  Attila Szabo; Attila Kovacs; Ede Frecska; Eva Rajnavolgyi
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

View more
  24 in total

1.  'Foxtrot' fumarate: a water-soluble salt of N,N-di-allyl-5-methoxytryptamine (5-MeO-DALT).

Authors:  Duyen N K Pham; Vamshikrishna Reddy Sammeta; Andrew R Chadeayne; James A Golen; David R Manke
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2021-03-19

Review 2.  Psilocybin for Trauma-Related Disorders.

Authors:  Amanda J Khan; Ellen Bradley; Aoife O'Donovan; Joshua Woolley
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 3.  N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.

Authors:  Edward James; Joachim Keppler; Thomas L Robertshaw; Ben Sessa
Journal:  Hum Psychopharmacol       Date:  2022-02-17       Impact factor: 2.130

4.  Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.

Authors:  Alan K Davis; Frederick S Barrett; Roland R Griffiths
Journal:  J Contextual Behav Sci       Date:  2019-11-16

5.  Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.

Authors:  Rafael L Lancelotta; Alan K Davis
Journal:  J Psychoactive Drugs       Date:  2020-03-09

6.  Psychedelics, Meditation, and Self-Consciousness.

Authors:  Raphaël Millière; Robin L Carhart-Harris; Leor Roseman; Fynn-Mathis Trautwein; Aviva Berkovich-Ohana
Journal:  Front Psychol       Date:  2018-09-04

7.  A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.

Authors:  Joseph J Palamar; Patricia Acosta
Journal:  Hum Psychopharmacol       Date:  2020-01-07       Impact factor: 1.672

8.  Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.

Authors:  Roland R Griffiths; Ethan S Hurwitz; Alan K Davis; Matthew W Johnson; Robert Jesse
Journal:  PLoS One       Date:  2019-04-23       Impact factor: 3.240

9.  Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies.

Authors:  Lee E Dunlap; Arya Azinfar; Calvin Ly; Lindsay P Cameron; Jayashri Viswanathan; Robert J Tombari; Douglas Myers-Turnbull; Jack C Taylor; Ana Cristina Grodzki; Pamela J Lein; David Kokel; David E Olson
Journal:  J Med Chem       Date:  2020-01-24       Impact factor: 7.446

10.  Engineering Safer Psychedelics for Treating Addiction.

Authors:  Jamie Peters; David E Olson
Journal:  Neurosci Insights       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.